About Alcresta
Alcresta is a Healthcare company based in Newton (United States) founded in 2011, and was acquired by Linden Capital Partners in March 2024. It operates as an enzyme-based products for gastrointestinal disorders are developed using immobilization technology. Alcresta has raised $95.89 million across 6 funding rounds from investors including Bessemer Venture Partners, Frazier Healthcare Partners and Athyrium Capital Management. The company has 52 employees. Its chief executive is Daniel Orlando. Alcresta offers products and services including RELiZORB and iLipase. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is Alcresta Therapeutics, Inc. Its competitors include Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Seed and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
Alcresta was founded in 2011 in Newton, United States, focusing on the biotechnology sector for gastrointestinal health. A platform technology is utilized to immobilize enzymes on insoluble carriers, aiding digestion and nutrient absorption. The flagship product, Relizorb, is designed as a cartridge mimicking pancreatic lipase function. Operations center on developing and advancing these enzyme-based therapeutics for clinical applications.
- Headquarters Newton, United States
- Employees 52
- Stage Acquired
- SectorsHealthcare
- Website alcresta.com
- Social LinkedIn
- Acquired by Linden Capital Partners (Mar 2024)
- Legal Name Alcresta Therapeutics, Inc.
- Total Equity Funding$95.89M (USD)
in 6 rounds
- Latest Funding Round$10M (USD), Series D
Feb 2020
- InvestorsBessemer Venture Partners
& 4 more
- Employee Count52
- Acquired byLinden Capital Partners
(Mar 2024)
Products & Services of Alcresta
Alcresta offers a comprehensive portfolio of products and services, including RELiZORB and iLipase.
Breaks down fats in enteral feeding for better absorption in patients.
Patented microbead technology for fat digestion in nutritional support.
Funding Insights of Alcresta
Alcresta has successfully raised a total of $95.89M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $95.89M
- Total Rounds 6
- Last Round Series D — $10M
- First Round $10M
(Apr 2012)
- Investors Count 4
All 6 funding rounds of Alcresta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $10M | Series D | – | – | – |
| Jan 2019 | $5M | Series D | – | – | – |
| Sep 2017 | $10M | Series D | – | – | – |
| Mar 2016 | $50.89M | Series C | – | Athyrium Capital Management, Bessemer Venture Partners | – |
| Jul 2013 | $10M | Series B | – | Third Rock Ventures, Frazier Healthcare Partners | – |
| Apr 2012 | $10M | Series A | – | Bessemer Venture Partners, Frazier Healthcare Partners | – |
5 investors in total: 5 institutional.
Investors in Alcresta
Alcresta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Bessemer Venture Partners, Frazier Healthcare Partners and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | – | athyrium.com | New York, United States | |
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Venture capital funding is provided to early-stage life science companies. | – | thirdrockventures.com | Boston, United States | |
Private equity investments are focused on the healthcare sector. | – | lindenllc.com | Chicago, United States |
Investor details for Alcresta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alcresta
39 people are tracked at Alcresta (12 in leadership, 6 in board & advisors, 21 in team); the tracked headcount is 52.
| Name | Role | Group |
|---|---|---|
Daniel Orlando | CEO | Leadership |
Jeffrey DiNardo | Senior Director Technical Operations | Leadership |
Ian V. | Chief Financial Officer | Leadership |
Jason Weiner | Chief Strategy Officer (cso) And Head Of Business Development | Leadership |
Chris Parrish | COO | Leadership |
Greta Loring | VP Research and New Product Development | Leadership |
Lee LoPiccolo | Sr. Director Global Supply Chain | Leadership |
Jim Kevil, MBA | VP Of Finance | Leadership |
William Scheinler | Chief Legal Officer | Leadership |
Anne Smith | Executive Assistant to Chairman and Chief Executive Officer | Leadership |
Eric McCord | Associate Director, Commercial Strategy & Analytics | Leadership |
Corey Starke | Senior Director, Commercial Operations | Leadership |
Steve Dubin | Director | Board & advisors |
Stephen Kraus | Director | Board & advisors |
Alexey Margolin | Director | Board & advisors |
Alan Muney | Director | Board & advisors |
Hondo Sen | Director | Board & advisors |
Jared Teo | Director | Board & advisors |
Jennifer Barber | Commercial Sales Training And Effectiveness Senior Manager | Team |
Maxwell Werman | Account Manager | Team |
19 more people are available in the full profile.
Complete people profiles for Alcresta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alcresta
4 dated milestones of Alcresta across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Alcresta is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series D, of $10.0M.
- Exit Acquired by Linden Capital Partners.
Competitors of Alcresta
Alcresta has 9 listed competitors in our database, 6 of them funded. They include Ironwood Pharma, Ardelyx, RedHill Biopharma, Cosmo Pharmaceuticals and Seed, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| redhillbio.com | 2009 | Ramat Gan, Israel | $13.5M | 183 | Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | |
| cosmopharma.com | 1996 | Dublin, Ireland | – | – | Therapeutics for gastrointestinal diseases are developed and provided. | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | – | Synbiotics are developed for simulating the gut microbiome. | |
| norgine.com | 1906 | Amsterdam, Netherlands | – | – | Proprietary therapeutic products for gastrointestinal diseases are developed and marketed. | |
| barinthusbio.com | 2016 | Harwell, United Kingdom | $209.71M | – | T-cell immunotherapeutics are developed for treating multiple diseases. | |
| bauschhealth.com | 1960 | Laval, Canada | – | 808 | Therapeutics for multiple diseases including dermatology and neurology are developed. | |
| calypsobiotech.com | 2013 | – | $36.39M | – | Antibody-based therapeutics are developed for gastrointestinal diseases. |
Detailed competitors of Alcresta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alcresta
The website of Alcresta (alcresta.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 40.9% vs previous month
Top companies in Gastroenterology
10 companies that operate in the same segment as Alcresta (Gastroenterology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Implantable battery-powered pumps for ascites removal are developed. | 2006 | Zurich, Switzerland | USD 35.5 M | – | – | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | – | 411 | |
Developer of electrosurgical system and range of flexible endoscopic instruments | 2003 | Chepstow, Monmouthshire, United Kingdom | USD 20.84 M | USD 8.08 M | 141 | |
Non-invasive biomarker tests for colorectal cancer are developed. | 2015 | St. Louis, Missouri, United States | USD 218.95 M | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | 2009 | Ramat Gan, Tel Aviv District, Israel | USD 13.5 M | USD 288.27 K | 35 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | 71 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alcresta
Complete news archive for Alcresta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alcresta
Alcresta was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Alcresta is headquartered in Newton, United States. It is registered at Newton, Massachusetts, United States.
Daniel Orlando is the current CEO of Alcresta.
Alcresta is a funded company, having raised a total of $95.89M across 6 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Apr 2012.
Alcresta has 52 employees.
Alcresta was founded in 2011 in Newton, United States, focusing on the biotechnology sector for gastrointestinal health. A platform technology is utilized to immobilize enzymes on insoluble carriers, aiding digestion and nutrient absorption. The flagship product, Relizorb, is designed as a cartridge mimicking pancreatic lipase function. Operations center on developing and advancing these enzyme-based therapeutics for clinical applications.
Alcresta's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Alcresta offers RELiZORB and iLipase.
Alcresta has 5 investors. Key investors include Bessemer Venture Partners, Frazier Healthcare Partners, Athyrium Capital Management, Third Rock Ventures, and Linden Capital Partners.
Alcresta operates through Alcresta Therapeutics, Inc..
Yes. Alcresta was acquired by Linden Capital Partners in March 2024.